<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02344940</url>
  </required_header>
  <id_info>
    <org_study_id>RJBC1401</org_study_id>
    <nct_id>NCT02344940</nct_id>
  </id_info>
  <brief_title>Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer</brief_title>
  <acronym>TTOS</acronym>
  <official_title>Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer: A Randomized, Controlled, Prospective, Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the safety of toremifene and tamoxifen therapy in premenopausal patients with&#xD;
      operable breast cancer by monitoring gynecological abnormality,blood lipid level,hepatic&#xD;
      abnormality,estrogen level and perimenopausal symptoms.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">August 2018</completion_date>
  <primary_completion_date type="Actual">August 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of ovarian cyst</measure>
    <time_frame>participants will be followed during the first year of endocrine therapy</time_frame>
    <description>Ovarian cyst is defined as a purely liquid-filled structure that was equal to or exceeded 2 cm in its largest diameter detected by transvaginal ultrasonography.Participants will be required to receive transvaginal ultrasonography every 3 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of endometrial thickening</measure>
    <time_frame>participants will be followed during the first year of endocrine therapy</time_frame>
    <description>Endometrial thickness as measured with transvaginal ultrasonography is equal to or exceeded 8mm.Participants will be required to receive transvaginal ultrasonography every 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of female hormones</measure>
    <time_frame>participants will be followed during the first year of endocrine therapy</time_frame>
    <description>Change of follicle stimulating hormone(FSH),luteinizing hormone(LH),estradiol(E2) as measured every 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of blood lipid</measure>
    <time_frame>participants will be followed during the first year of endocrine therapy</time_frame>
    <description>Change of blood lipid as measured every 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of liver function</measure>
    <time_frame>participants will be followed during the first year of endocrine therapy</time_frame>
    <description>change of blood lipid as measured every 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of fatty liver</measure>
    <time_frame>participants will be followed during the first year of endocrine therapy</time_frame>
    <description>Incidence of fatty liver as examined by liver ultrasound every 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of Kupperman index</measure>
    <time_frame>participants will be followed during the first year of endocrine therapy</time_frame>
    <description>change of Kupperman index as measured every 3 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>toremifene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients who will be treated with toremifene.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tamoxifen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients who will be treated with tamoxifen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toremifene</intervention_name>
    <description>patients will take toremifene 60 mg qd.</description>
    <arm_group_label>toremifene</arm_group_label>
    <other_name>Fareston</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>patients will take tamoxifen 10 mg bid.</description>
    <arm_group_label>tamoxifen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women aged ≥18 years, premenopausal&#xD;
&#xD;
          2. Histologically confirmed invasive breast cancer by core needle biopsy, hormonal&#xD;
             receptor positive, defined as estrogen receptor(ER)/progesterone receptor(PR) positive&#xD;
&#xD;
          3. Patients must have received standard local therapy: normalized modified radical&#xD;
             mastectomy or breast conserving surgery with negative margin and post-surgical&#xD;
             radiotherapy. Patient should completed adjuvant therapy according to conditions,&#xD;
             including adjuvant radiotherapy, neoadjuvant or adjuvant chemotherapy.&#xD;
&#xD;
          4. Leukocyte ≥ 3*109/L; Platelets ≥ 75*109/L; Serum glutamate oxaloacetate(AST/SGOT) or&#xD;
             serum glutamic-pyruvic transaminase(ALT/SGPT) &lt;2.5 times of upper limit of normal&#xD;
             (UNL) range Serum creatinine/blood urea nitrogen(BUN) ≤ upper limit of normal (UNL)&#xD;
             range; Written informed consent according to the local ethics committee requirements.&#xD;
&#xD;
          5. Has Eastern Cooperative Oncology Group(ECOG) Performance Score 0-2;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed hormonal receptor negative.&#xD;
&#xD;
          2. Have received neoadjuvant/adjuvant endocrine therapy.&#xD;
&#xD;
          3. With metastatic tumor.&#xD;
&#xD;
          4. Family history of endometrial cancer or ovarian cancer or any other kind of&#xD;
             gynecological malignant tumor.&#xD;
&#xD;
          5. Have already been detected of ovarian abnormality or endometrial thickening by&#xD;
             transvaginal ultrasound.&#xD;
&#xD;
          6. With any of complications that will increase sex hormone level: pituitary&#xD;
             adenoma，ovarian tumor, thymic cancer，etc.&#xD;
&#xD;
          7. With any of complications that will decrease sex hormone&#xD;
             level:hyperthyroidism，hypothyroidism，liver cirrhosis，severe malnutrition，Turner's&#xD;
             syndrome，sex hormone synthetase deficiency, intracranial tumor, pituitary atrophy,&#xD;
             etc.&#xD;
&#xD;
          8. Ovarian ablation or suppression&#xD;
&#xD;
          9. With severe non-malignant co-morbidity that will influence long-term follow up.&#xD;
&#xD;
         10. With severe hepatic dysfunction, Child-Pugh C.&#xD;
&#xD;
         11. With severe cardiac dysfunction, New York Heart Association (NYHA) grading III or&#xD;
             worse.&#xD;
&#xD;
         12. Known severe hypersensitivity to any drugs in this study;&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kunwei Shen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>January 5, 2015</study_first_submitted>
  <study_first_submitted_qc>January 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <last_update_submitted>September 23, 2019</last_update_submitted>
  <last_update_submitted_qc>September 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Kunwei Shen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>operable</keyword>
  <keyword>premenopausal</keyword>
  <keyword>endocrine therapy</keyword>
  <keyword>safety</keyword>
  <keyword>tamoxifen</keyword>
  <keyword>toremifene</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Toremifene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

